Author: Beghou Consulting

As big tech’s health care disruption efforts flag, biopharma companies can step up to empower patients and improve care, Rohit Gupta writes in Pharmaceutical Executive.

With data proliferating rapidly in the biopharma industry, it’s crucial that commercial teams bring disjointed data together into holistic data sets. In Med Ad News, Justin Khalifa presents four keys to success.

COVID-19 has kept medical science liaisons grounded for more than a year. In response, they’ve been busy mastering the art of the digital connection to continue delivering crucial scientific information to healthcare practitioners and key opinion leaders. In PharmaVOICE, Rohit Gupta discusses the changing role of medical science liaisons as a result of the COVID-19 pandemic.

As new legislation and regulations improve data privacy and increase data portability, patients will have the ability to compile data across doctors, pharmacies and health apps into a personal health portal. In PM360, Erik Cruz and Piotr Kula how this change to the data landscape offers biopharma companies the opportunity to improve insights into patient treatment journeys and boost access to life-saving therapies.

A sales “call” doesn’t mean what it used to and now extends well beyond a face-to-face meeting. Hence, drug manufacturers should think in terms of “touchpoints” instead of traditional “calls.” In Pharmaceutical Commerce, Erik Cruz, Kevin Frymire and Dan Schulman describe how biopharma companies can account for pandemic-driven changes in HCP engagement and improve sales force design and customer targeting efforts.

As biopharma companies eye product launches in a commercial environment that has been transformed by the COVID-19 pandemic, they must adjust their launch preparations to account for a more complex, fragmented and dynamic landscape. In Pharmaceutical Executive, Kevin Frymire, Dan Schulman and David Laros explain how companies can embrace launch agility.